-37%

est. 2Y upside i

HealthcareSeries B

Streamline, comply, and save 50-70% in UM operational costs at outset safely with ClarityCare's AI-powered system, which reduces your administrative burden and lets you focus on patient care.

Rank

#426

Sector

Healthcare AI

Est. Liquidity

~4Y

Data Quality

Data: Low

ClarityCare AI presents a strong upside opportunity driven by a massive market tailwind from the CMS-0057-F mandate and high demand for AI in healthcare.

Last updated: March 10, 2026

Bull (35%)+275%

ClarityCare AI leverages the CMS-0057-F mandate to become a dominant player in AI-driven prior authorization, expanding rapidly into payment integrity and clinical programs. Strategic partnerships with major payers and providers drive revenue to over $150M by 2028, justifying a valuation of ~$937.5M (3.75x current estimated valuation) at acquisition or IPO.

Base (40%)+100%

ClarityCare AI secures a solid foothold in the prior authorization market, growing steadily by capturing mid-tier payer and TPA clients. Revenue reaches ~$75M by 2028, leading to an acquisition or IPO at a valuation of ~$500M (2x current estimated valuation), reflecting consistent execution and strong product-market fit.

Bear (25%)-60%

Increased competition from well-funded incumbents or other specialized AI solutions, coupled with slower-than-expected adoption or unforeseen regulatory hurdles, limits ClarityCare AI's market penetration. Revenue growth stalls, leading to a down round or acquisition at a significantly reduced valuation of ~$100M, wiping out most common stock value given the preference stack.

Est. time to liquidity~4.0 years

Preference Stack Risk

high

Investors hold $46M in liquidation preferences, representing 18.4% of the estimated $250M post-money Series B valuation. In an exit at or below $250M, common stock value would be significantly impacted.

Dilution Risk

moderate

As a Series B company, it is likely to undergo 1-2 more funding rounds before a liquidity event, which will lead to further dilution of existing equity holders.

Secondary Liquidity

none

There is no indication of active secondary markets or tender offers for ClarityCare AI's equity at this early stage.

Questions to Ask at the Interview

Strategic questions based on ClarityCare's data — designed to show you've done your homework.

  • 1

    “Given the CMS-0057-F mandate, how is ClarityCare AI prioritizing its go-to-market strategy to capture market share from payers who need to comply by 2027, especially against larger, established players like Availity or Cohere Health?”

  • 2

    “With no publicly disclosed revenue and only ~9 employees, what are the key milestones and metrics (beyond funding rounds) that ClarityCare AI is focused on to demonstrate traction and validate its estimated ~$250M valuation over the next 12-18 months?”

  • 3

    “Considering the Series B funding and the estimated preference stack, what is the company's anticipated timeline and strategy for a liquidity event (IPO or acquisition), and how does the company plan to ensure meaningful returns for common stock holders?”

Community

Valuation Sentiment

Our model estimates -37% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.